SQLite Web: event_store.db

Update row sig_f95bbcc4fe88 in signals

id

Primary key. TEXT

event_id

TEXT NOT NULL

watcher_id

TEXT

signal_type

TEXT NOT NULL

value

{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1723980/0001213900-26-041765.txt","as_of":"2026-04-10T03:04:31.796915+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1723980/0001213900-26-041765.txt","company":"China SXT Pharmaceuticals, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1723980/0001213900-26-041765.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_9e954e7c1220ec4b","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1723980/0001213900-26-041765.txt","content_type":"text/plain","enriched_at":"2026-04-10T03:27:39.443720+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1723980/0001213900-26-041765.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1723980/0001213900-26-041765.txt","source_event_id":"evt_e95c3c3557b1","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"6-K","fp":"362615b3025faef1","kind":"sec_filing","published_at":"20260409","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.86,"dates_mentioned":["2026-04-07","2026-04-09","2026-04-10","2025-11-10","2025-12-01"],"entities":[{"asset_class":"equity","name":"China SXT Pharmaceuticals, Inc.","relevance":"high","symbol":"","type":"issuer"},{"asset_class":"professional_services","name":"Appleby","relevance":"medium","symbol":"","type":"legal_counsel"},{"asset_class":"contract","name":"Securities Purchase Agreement","relevance":"high","symbol":"","type":"agreement"},{"asset_class":"sec_filing","name":"Form F-3 (File No. 333-291428)","relevance":"medium","symbol":"","type":"registration_statement"},{"asset_class":"sec_filing","name":"Prospectus supplement filed April 9, 2026","relevance":"medium","symbol":"","type":"prospectus_document"}],"event_type":"listing","information_gaps":["The text provided does not include Exhibit 10.1 (Securities Purchase Agreement) details beyond the summary statements in the 6-K.","The text provided does not specify the identity of the \u201ccertain investors.\u201d","The text provided does not state the exact amount of net proceeds or any breakdown of intended uses beyond \u201cgeneral corporate purposes.\u201d","The text provided does not describe any changes versus a prior known state beyond the fact that this 6-K was filed (no prior filing content is included in the prompt)."],"key_facts":["Form 6-K filed for the month of April 2026 by China SXT Pharmaceuticals, Inc.","On April 7, 2026, the Company entered into a securities purchase agreement with certain investors for an offering of 2,000,000 Class A ordinary shares (no par value).","The shares were to be issued pursuant to a registration statement on Form F-3 (File No. 333-291428) filed November 10, 2025 and effective December 1, 2025, and a prospectus supplement filed April 9, 2026.","Aggregate gross proceeds are expected to be approximately $760,000 before deducting other offering expenses payable by the Company.","The offering is expected to close on April 9, 2026, subject to customary closing conditions.","The Company intends to use net proceeds for general corporate purposes.","The 6-K states that the full description is qualified by reference to the full text of the Securities Purchase Agreement filed as Exhibit 10.1.","An opinion of Appleby relating to validity of the securities is filed as Exhibit 5.1.","The Appleby opinion states the offering price is US$0.38 per share for aggregate gross proceeds of US$760,000 and is addressed in connection with the prospectus supplement to the prospectus dated 10 November 2025."],"numeric_claims":[{"label":"shares_offered","value":"2,000,000 Class A ordinary shares"},{"label":"expected_gross_proceeds_usd","value":"~$760,000"},{"label":"offering_price_per_share_usd","value":"$0.38 per share"},{"label":"closing_date","value":"April 9, 2026"}],"primary_claim":"On April 7, 2026, China SXT Pharmaceuticals, Inc. entered into a securities purchase agreement to sell and issue 2,000,000 Class A ordinary shares, expected to generate aggregate gross proceeds of approximately $760,000.","relevance_score":0.72,"sentiment":"neutral","source_quality":"high","summary":"China SXT Pharmaceuticals, Inc. filed a Form 6-K reporting entry into a securities purchase agreement for an offering of 2,000,000 Class A ordinary shares. The company expects aggregate gross proceeds of about $760,000 and intends to use net proceeds for general corporate purposes.","topics":["SEC filing","securities purchase agreement","equity offering","share issuance","use of proceeds","exhibits 5.1"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 6-K \u00b7 China SXT Pharmaceuticals, Inc. \u00b7 Filed 20260409","ticker":"SXTC","tickers":["SXTC"],"title":"SXTC filed 6-K","url":"https://www.sec.gov/Archives/edgar/data/1723980/0001213900-26-041765.txt"}

TEXT NOT NULL

threshold

TEXT

direction

TEXT

severity

TEXT

window

TEXT

source

TEXT NOT NULL

reason_trace

TEXT

dedupe_key

TEXT NOT NULL

throttle_s

INTEGER (default 0

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel